|
|
|
|
Adding Adefovir (Hepsera) to Lamivudine (Epivir-HBV) Extends Biochemical Response, But May Cause Kidney Proble
Several nucleoside/nucleotide analogs are effective against , but when they are used alone, the virus can develop resistance relatively easily, thereby compromising long-term treatment success.Combining these agents, however, slows the emergence of...
|
|
|
Mylan Strengthens Portfolio With Generic Diabetes Drugs
Mylan Inc.(MYL) has entered into an agreement with Takeda Pharmaceutical for two type II diabetes drugs Actoplus Met and Actos, which recorded 2009 sales of $459 million and $3.4 billion, respectively. Following the agreement, Mylan will be able to launch...
|
|
|
Mylan Strengthens Portfolio - Analyst Blog
Mylan Inc.( MYL ) has entered into an agreement with Takeda Pharmaceutical for two type II diabetes drugs Actoplus Met and Actos, which recorded 2009 sales of $459 million and $3.4 billion, respectively. Following the agreement, Mylan will be able to...
|
|
|
Combination of Lamivudine and Adefovir Therapy in HBeAg-Positive Chronic Hepatitis B Patients With Poor Response to Adefovir Monotherapy
What is the effect of adding lamivudine to adefovir dipivoxil monotherapy in chr Combination of Lamivudine and Adefovir Therapy in HBeAg-Positive Chronic Hepatitis B Patients With Poor Response to Adefovir Monotherapy.
|
|
|
Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection
Cooper DA et al.Twicedaily maraviroc was not noninferior to efavirenz at 50 copies/mL in the primary analysis. However, 15% of patients would have been ineligible for inclusion by a more sensitive screening assay. Maraviroc versus Efavirenz, Both in...
|
|
|
Add-on Combination Therapy With Adefovir Dipivoxil Induces Renal Impairment in Patients With Lamivudine-Refrac
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
Achillion Announces Positive 96-Week Data for Elvucitabine at the 17th Annual Conference on Retroviruses and O
(GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc.(Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the presentation of additional...
|
|
|
Achillion Announces Positive 96-Week Data for Elvucitabine at the 17th Annual Conference on Retrovir
NEW HAVEN, Conn., Feb.17, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. , a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the presentation of additional...
|
|
|
Achillion Announces Positive 96-Week Data for Elvucitabine at the 17th Annual Conference on Retroviruses and O
NEW HAVEN, Conn., Feb.17, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the presentation of...
|
|
|
Achillion Pharma (ACHN) Updates on Elvucitabine Phase 2
Achillion Pharmaceuticals, Inc.(NASDAQ: ACHN) today announced the presentation of additional positive safety and efficacy results from its Phase 2 trial studying elvucitabine in patients infected with Human Immunodeficiency Virus (HIV). The new data were...
|
|
|
Hepatitis B Surface Antigen Loss during Treatment with Entecavir (Baraclude) or Lamivudine (Epivir-HBV)
Study ETV-022 was a Phase 3 clinical trial comparing entecavir (0.5 mg/day) versus lamivudine (100 mg/day) in more than 700 previously untreated HBeAg positive chronic hepatitis B patients with elevated alanine transaminase (ALT) levels and compensated liver...
|
|
|
HIV/AIDS Therapy: Study data from GlaxoSmithKline provide new insights into HIV/AIDS therapy
Today's Medical & Research News HIV/AIDS Therapy Study data from GlaxoSmithKline provide new insights into HIV/AIDS therapy February 11th, 2010 Printer-Friendly Version State:NC Country:United States HIV/AIDS Therapy Abacavir Anti-HIV Anti-Infectives...
|
|
|
Method for measuring resistance of a patient HIV-2 to protease inhibitors
Title: United States Patent: 7,632,635 Inventors: Telles; Jean-Noel (Paris, FR), Brun-Vezinet; Francoise (Paris, FR), Descamps; Diane (Paris, FR) Assignee: Biomerieux (Marcy l'Etoile, FR), Assistance Publique-Hopitaux de Paris (Paris, FR) Appl.No.: 10/865...
|
